| Generic name | Ponatinib |
| Pronunciation | poe-NA-ti-nib |
| Brand name(s), other common name(s) | Iclusig® |
| Drug type | Tyrosine kinase inhibitor |
| How the drug is given | By mouth |
Indications and Usage
Ponatinib is FDA approved for the treatment of adult patients with:
- Chronic phase (CP) chronic myeloid leukemia (CML) with resistance or intolerance to at least two prior kinase inhibitors.
- Accelerated phase (AP) or blast phase (BP) CML or Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) for whom no other kinase inhibitors are indicated.
- T315I-positive CML (chronic phase, accelerated phase, or blast phase) or T315I-positive Ph+ ALL.
Limitations of Use: Iclusig is not indicated and is not recommended for the treatment of patients with newly diagnosed CP-CML.
Side effects needing medical attention
Hypertension; rash; abdominal pain; fatigue; dizziness; headache; cough; dry skin; constipation; joint pain; nausea; diarrhea; vomiting; fever; low platelets; low red blood cells; low neutrophils; low level of lymphocytes; low white blood cell count; cardiac failure; pneumonia; respiratory tract infection, urinary tract infection; peripheral neuropathy; back pain; muscle spasms; bone pain; fatigue.
The risk of vascular occlusive events (arterial and venous thrombosis and occlusions, including fatal myocardial infarction, stroke, stenosis of large arterial vessels of the brain, severe peripheral vascular disease, and the need for urgent revascularization procedures) and heart failure have been reported with ponatinib.
For information on how to manage the costs of drug therapy, please see Financial Support, or to speak with an Information Specialist, call (800) 955-4572.